Literature DB >> 8771057

Possible relevance of phospholipid abnormalities and genetic interactions in psychiatric disorders: the relationship between dyslexia and schizophrenia.

D F Horrobin1, A I Glen, C J Hudson.   

Abstract

The fatty acids of cell membrane phospholipids are essential for normal membrane structures, for the functioning of membrane-bound and membrane-associated proteins and for normal cell-signalling responses. In dyslexia, there is evidence for reduced incorporation of docosahexaenoic acid and arachidonic acid into cell membranes, while in schizophrenia, there is evidence for an increased rate of docosahexaenoic acid and arachidonic acid loss from membranes because of enhanced phospholipase A2 activity. The presence of both defects will cause a much greater degree of abnormality than either one alone. It is hypothesized that unequivocal clinical schizophrenia may occur when both genes are present in the same individual. The dyslexia gene along will produce dyslexia while the schizophrenia gene alone may produce bipolar or schizoaffective disorders. These proposals could explain: 1. The reduced asymmetry of the brain, especially of the planum temporale in both schizophrenia and dyslexia; 2. The schizotypal personality characteristics of dyslexics; 3. The increased risks of dyslexia in families with a schizophrenic proband; 4. The increased risks of bipolar and schizoaffective disorders in families with a schizophrenic proband; 5. The earlier onset and possibly increased severity of both disorders in males since females have a lower requirement for arachidonic acid and docosahexaenoic acid; 6. The absence of selective pressure against schizophrenia since reproduction would be impaired only when the schizophrenic gene coexisted with a dyslexic gene. The schizophrenic gene alone might even lead to improved reproductive performance.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8771057     DOI: 10.1016/0306-9877(95)90246-5

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  8 in total

1.  Association studies of cytosolic phospholipase A2 polymorphisms and schizophrenia among two independent family-based samples.

Authors:  K V Chowdari; B Brandstaetter; P Semwal; T Bhatia; S Deshpande; R Reddy; J Wood; C R Weinberg; B K Thelma; V L Nimgaonkar
Journal:  Psychiatr Genet       Date:  2001-12       Impact factor: 2.458

2.  Dyslexia and familial high blood pressure: an observational pilot study.

Authors:  K Taylor; J Stein
Journal:  Arch Dis Child       Date:  2002-01       Impact factor: 3.791

Review 3.  Research strategies and priorities to improve the lives of people with schizophrenia: executive summary of the Ernst Strüngmann Forum on schizophrenia.

Authors:  Steven M Silverstein; Bita Moghaddam; Til Wykes
Journal:  Schizophr Bull       Date:  2014-01-28       Impact factor: 9.306

4.  Dynamics of docosahexaenoic acid metabolism in the central nervous system: lack of effect of chronic lithium treatment.

Authors:  M C Chang; J M Bell; A D Purdon; E G Chikhale; E Grange
Journal:  Neurochem Res       Date:  1999-03       Impact factor: 3.996

Review 5.  Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications.

Authors:  J K Yao; R D Reddy; D P van Kammen
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 6.  Long-chain polyunsaturated fatty acids in childhood developmental and psychiatric disorders.

Authors:  Alexandra J Richardson
Journal:  Lipids       Date:  2004-12       Impact factor: 1.880

Review 7.  Recent Reports on Redox Stress-Induced Mitochondrial DNA Variations, Neuroglial Interactions, and NMDA Receptor System in Pathophysiology of Schizophrenia.

Authors:  Narasimha M Beeraka; Marco F Avila-Rodriguez; Gjumrakch Aliev
Journal:  Mol Neurobiol       Date:  2022-01-27       Impact factor: 5.590

Review 8.  Significance of long-chain polyunsaturated fatty acids (PUFAs) for the development and behaviour of children.

Authors:  Jan Philipp Schuchardt; Michael Huss; Manuela Stauss-Grabo; Andreas Hahn
Journal:  Eur J Pediatr       Date:  2009-08-12       Impact factor: 3.183

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.